Diagnostic testing for Clostridium difficile: a comprehensive survey of laboratories in England.

S. Goldenberg,S. Goldenberg,G. French,G. French

DOI: https://doi.org/10.1016/j.jhin.2011.03.030

IF: 8.944

2011-09-01

Journal of Hospital Infection

Abstract:

What problem does this paper attempt to address?

Diagnosis of Clostridioides difficile infection and impact of testing

Virginie F. Viprey,Emma Clark,Kerrie A. Davies

DOI: https://doi.org/10.1099/jmm.0.001939

2024-12-05

Journal of Medical Microbiology

Abstract:Diagnosis of Clostridioides difficile infection (CDI) remains challenging as it involves in the first instance recognition (clinical awareness) of the patients' symptoms for clinical suspicion of CDI to warrant testing, and secondly, different laboratory tests have been described for CDI. Due to the overwhelming amount of information in the literature on CDI tests and their performance, with separately published guidelines, this review aims to provide a comprehensive but concise summary of the current state of CDI diagnostic testing. Current knowledge and the impact of using different laboratory diagnostic procedures for CDI, including the most recommended approach as a two-step algorithm and the concept of diagnostic stewardship, are being discussed. This review provides an updated overview and valuable take-home messages in the field of CDI laboratory testing and highlights that timely diagnosis is important for the clinical management of CDI and that the recommended testing procedures are increasingly becoming more widely accepted.

microbiology
Diagnostic Guidance for C. difficile Infections

Joffrey van Prehn,Monique J T Crobach,Amoe Baktash,Nikolas Duszenko,Ed J Kuijper

DOI: https://doi.org/10.1007/978-3-031-42108-2_3

Abstract:Diagnosis of Clostridioides difficile infection (CDI) can be challenging. First of all, there has been debate on which of the two reference assays, cell cytotoxicity neutralization assay (CCNA) or toxigenic culture (TC), should be considered the gold standard for CDI detection. Although the CCNA suffers most from suboptimal storage conditions and subsequent toxin degradation, TC is reported to falsely increase CDI detection rates as it cannot differentiate CDI patients from patients asymptomatically colonised by toxigenic C. difficile. Several rapid assays are available for CDI detection and fall into three broad categories: (1) enzyme immunoassays for glutamate dehydrogenase, (2) enzyme immunoassays or single-molecule array assays for toxins A/B and (3) nucleic acid amplification tests detecting toxin genes. All three categories have their own limitations, being suboptimal specificity and/or sensitivity or the inability to discern colonised patients from CDI patients. In light of these limitations, multi-step algorithmic testing has been advocated by international guidelines (IDSA/SHEA and ESCMID) in order to optimize diagnostic accuracy. As a result, a survey performed in 2018-2019 in Europe revealed that most of all hospital sites reported using more than one test to diagnose CDI. CDI incidence rates are also influenced by sample selection criteria, as several studies have shown that if not all unformed stool samples are tested for CDI, many cases may be missed due to an absence of clinical suspicion. Since methods for diagnosing CDI remain imperfect, there has been a growing interest in alternative testing strategies like faecal microbiota biomarkers, immune modulating interleukins, cytokines and imaging methods. At the moment, these alternative methods might play an adjunctive role, but they are not suitable to replace conventional CDI testing strategies.
Epidemiological and clinical characteristics of Clostridium difficile infection in patients with refractory inflammatory bowel disease

Sai-zheng LIN,Jian-ting CAI,Yan CHEN,Qun-fen CAO,Yong-hua CHEN

DOI: https://doi.org/10.11816/cn.ni.2017-170024

2017-01-01

Abstract:OBJECTIVE To explore the epidemiological and clinical characteristics of Clostridium difficile infections in patients with refractory inflammatory bowel disease so as to provide guidance for clinical prevention and treatment of the C.difficile infections.METHODS A total of 92 patients with refractory inflammatory bowel disease who were treated in hospitals from Jan 2013 to Jan 2016 were enrolled in the study,the prevalence of C.difficile infections in stools was detected by using fluorescent enzyme immunoassay,and the clinical characteristics of the refractory inflammatory bowel disease patients with C.difficile infections were observed.RESULTS The incidence rate of C.difficile infections was 20.5％ in the patients with refractory inflammatory bowel disease,20.83 ％ in the patients with ulcerative colitis,20.45 ％ in the patients with Crohn disease.The incidence rate of C.difficile infections was significantly increased in the patients with refractory inflammatory bowel disease who used antibiotics,vancomycin,or were in active stage (P＜0.05).The incidence rate of C.difficile infections was 44.44％ in the patients with severe ulcerative colitis,5.56％ in the patients with moderate ulcerative colitis,8.33％ in the patients with mild ulcerative colitis,and there was significant difference (P＜0.05).The incidence rate of C.difficile infection was significantly increased in the patients with colon involved (P＜0.05);the incidence rate of C.difficile infections was significantly increased in the Crohn disease patients with colon involved (P＜0.05).CONCLUSION The incidence rate of C.difficile infections is relatively high in the patients with refractory inflammatory bowel disease,which is associated with the use of antibiotics,vancomycin,range of motion,severity of disease,and colon involvement.
High Prevalence of Multistep Algorithms in Diagnostic Clostridioides difficile Laboratory Testing

Kaede V Sullivan,Rhona J Souers,Erica Hillesland,Dylan Pillai,Daniel D Rhoads,Robin Rolf,Patricia J Simner,Christina M Wojewoda,Carol A Rauch

DOI: https://doi.org/10.5858/arpa.2023-0434-CP

2024-08-05

Abstract:Context.—: Laboratory testing practices for diagnosis of Clostridioides difficile infection (CDI) have evolved in response to published guidelines, availability of highly sensitive nucleic acid amplification tests (NAATs), perceived problems with the specificity of NAATs, and CDI reporting requirements. Objective.—: To assess the current state of laboratory practice for diagnostic CDI testing. Design.—: An optional 8-item supplemental questionnaire was distributed in December 2019 to the 1374 laboratories participating in the College of American Pathologists C difficile Detection (CDF) proficiency testing program challenge CDF-C. Results.—: Of 1374 CDF-C participants, 1160 (84.4%) responded, predominantly representing laboratories based in the United States (1077 of 1160; 92.8%). The majority reported using a multistep testing algorithm (684 of 1159; 59.0%). Initial testing with a glutamate dehydrogenase and toxin A/B combination test followed by NAAT for discrepant results was the most common testing method (360 of 1146; 31.4%). NAAT alone (299 of 1146; 26.1%) was next, then NAAT followed by an assay that included toxin A/B enzyme immunoassay if NAAT is positive (258 of 1146; 22.5%). Only 5.4% (62 of 1146) reported using toxin A/B immunoassay alone. Most respondents (1093 of 1131; 96.6%) reported rejecting CDI tests on formed stool, but rejection of CDI testing in pediatric patients was uncommon (211 of 1131; 18.7%). Rejection of CDI testing in patients using laxatives was reported more often by US-based respondents (379 of 1054 [36.0%] versus 9 of 77 [11.7%], P < .001). Conclusions.—: Multistep algorithms for CDI diagnosis are widely used in line with published recommendations. Most respondents reported rejection of formed stool for CDI testing, but few reported rejection of testing in infants and patients taking laxatives, suggesting these may be areas of opportunity for laboratories to pursue in improving CDI testing practices.
Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture

Michel Delmée,Johan Van Broeck,Anne Simon,Michèle Janssens,Véronique Avesani

DOI: https://doi.org/10.1099/jmm.0.45844-0

Abstract:A routine protocol for diagnosing Clostridium difficile-associated diarrhoea (CDAD) based on both faecal-cytotoxin detection and toxigenic culture was adopted by the microbiology laboratory of the St Luc-UCL University Hospital in Brussels in 1997. A toxigenic culture is a faecal culture followed, in the case of positivity, by a direct immunoassay on colonies to detect toxin A production. The results obtained over the past 7 years in the hospital are reviewed here. A total of 10,552 diarrhoeal stools from 7042 patients were analysed, of which 9494 were negative for all tests. A total of 1058 samples (10 %) from 794 patients were culture-positive, of which 460 (4.4 %) were positive for a faecal cytotoxin. The remaining 598 cultures were tested for toxin A on colonies; 355 of them were positive, which is 3.4 % of the total, and the remaining 243 (2.3 %) were negative. The positivity of the faecal-cytotoxin assay was statistically linked to the number of colonies observed on the culture plate. In conclusion, over a 7 year period, toxigenic culture allowed the diagnosis of 355 cases of CDAD that would have been missed by a protocol using a faecal-cytotoxin assay alone. In terms of both patient care, prevention of environmental contamination and prevention of risk of a hospital outbreak, it is proposed that these results justify the recommendation to perform both faecal-toxin assay and culture in routine medical practice.
A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018

Virginie F Viprey,Georgina L Davis,Anthony D Benson,Duncan Ewin,William Spittal,Jon J Vernon,Maja Rupnik,Alice Banz,Florence Allantaz,Philippe Cleuziat,the COMBACTE-CDI National Coordinators,Mark H Wilcox,Kerrie A Davies and on behalf of the COMBACTE-CDI consortium

DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.26.2100704

2022-07-01

Eurosurveillance

Abstract:Background There is a paucity of data on community-based Clostridioides difficile infection (CDI) and how these compare with inpatient CDI. Aim To compare data on the populations with CDI in hospitals vs the community across 12 European countries. Methods For this point-prevalence study (July–November 2018), testing sites sent residual diagnostic material on sampling days to a coordinating laboratory for CDI testing and PCR ribotyping (n = 3,163). Information on whether CDI testing was requested at the original site was used to identify undiagnosed CDI. We used medical records to identify differences between healthcare settings in patient demographics and risk factors for detection of C. difficile with or without free toxin. Results The CDI positivity rate was 4.4% (country range: 0–16.2) in hospital samples, and 1.3% (country range: 0–2.2%) in community samples. The highest prevalence of toxinotype IIIb (027, 181 and 176) was seen in eastern European countries (56%; 43/77), the region with the lowest testing rate (58%; 164/281). Different predisposing risk factors were observed (use of broad-spectrum penicillins in the community (OR: 8.09 (1.9–35.6), p = 0.01); fluoroquinolones/cephalosporins in hospitals (OR: 2.2 (1.2–4.3), p = 0.01; OR: 2.0 (1.1–3.7), p = 0.02)). Half of community CDI cases were undetected because of absence of clinical suspicion, accounting for three times more undiagnosed adults in the community compared with hospitals (ca 111,000 vs 37,000 cases/year in Europe). Conclusion These findings support recommendations for improving diagnosis in patients presenting with diarrhoea in the community, to guide good practice to limit the spread of CDI.

infectious diseases
Clostridium difficile Diagnostics in Long-Term Care Facilities

Rishitha Bollam,Nisa Desai,Laurie Archbald-Pannone

DOI: https://doi.org/10.1007/978-3-030-29772-5_5

2019-11-15

Abstract:Clostridium difficile (C. difficile) infection (CDI) is an increasing common healthcare-associated infection and disproportionally affects our elderly patients and patients in long-term care facilities (LTCFs) (Asempa and Nicolau, Clin Interv Aging. 12:1799, 2017). As described in other chapters of this book, patients with CDI can have multiple loose or watery stools in 1 day causing extreme dehydration, electrolyte disarray, sepsis, toxic megacolon, and even death. With the increasing prevalence and severity of CDI over the past decade, clinicians are understandably concerned when suspecting CDI in one of their patients and keen to test to see if C. difficile is present in the stool. However, the presence of C. difficile in the stool is not sufficient to diagnose CDI, and the current diagnostic tests commercially available are complex. CDI is a toxin-mediated infection and therefore, diagnostic assays often focus on the presence of toxin as a necessary component to develop infection, as opposed to colonization with non-toxigenic C. difficile strain. Nucleic acid amplification test (NAAT), enzyme immunoassay (EIA), and cytotoxigenic culture (CC) and cell cytotoxicity assay (CCTA) are available options. A multistep algorithmic approach has been recommended to utilize the above-mentioned testing. Diagnostics are challenged by decreased immune response in the elderly and delays in an LTCF setting. In this chapter, we will describe the different C. difficile diagnostic tests and their appropriate use in clinical practice in long-term care patients.
Nationwide Survey for Current Status of Laboratory Diagnosis of Clostridioides difficile Infection in Korea

Hae-Sun Chung,Jeong Su Park,Bo-Moon Shin,Hyeon Mi Yoo,Heejung Kim,Jihyun Cho,Chae Hoon Lee,Nam Hee Ryoo,Jae-Seok Kim,Jae-Woo Chung,Ki Ho Hong,You Sun Kim,Young-Seok Cho

DOI: https://doi.org/10.3346/jkms.2022.37.e38

2022-01-01

Journal of Korean Medical Science

Abstract:BACKGROUND: The interest in Clostridioides difficile infection (CDI) has increased, and the choice of assays became wider since the first national survey in Korea on CDI diagnosis in 2015. We conducted a survey of the domestic CDI assays with more varied questions to understand the current situation in Korea.METHODS: In April 2018, about 50 questions on the current status of CDI assays and details on implementation and perceptions were written, and a survey questionnaire was administered to laboratory medicine specialists in 200 institutions.RESULTS: One-hundred and fifty institutions responded to the questionnaire, of which 90 (60.0%) including one commercial laboratory, performed CDI assays. The toxin AB enzyme immunoassay (toxin AB EIA), nucleic acid amplification test (NAAT), and C. difficile culture, glutamate dehydrogenase assay, alone or in combination with other assays, were used in 75 (84.3%), 52 (58.4%), 35 (36.0%), and 23 (25.8%), respectively, and 65 (73.0%) institutions performed a combination of two or more assays. The sensitivity of toxin AB EIA was more negatively perceived, and that on specificity was more positively perceived. The perception of sensitivity and specificity of NAAT was mostly positive. Perception on the algorithm test projected it as useful but in need of countermeasures. Sixty-three (73.3%) institutions responded that they performed surveillance on CDI.CONCLUSION: This study provides useful evidence on the current status of CDI laboratory diagnosis in Korea as well as on items that require improvement and is thought to aid in standardizing and improving the CDI laboratory diagnosis in Korea.

medicine, general & internal
Assessment Of Clostridium Difficile Infections By Quantitative Detection Of Tcdb Toxin By Use Of A Real-Time Cell Analysis System

Alex B. Ryder,Ying Huang,Haijing Li,Min Zheng,Xiaobo Wang,Charles W. Stratton,Xiao Xu,Yi-Wei Tang

DOI: https://doi.org/10.1128/JCM.01104-10

2010-01-01

Journal of Clinical Microbiology

Abstract:We explored the use of a real-time cell analysis (RTCA) system for the assessment of Clostridium difficile toxins in human stool specimens by monitoring the dynamic responses of the HS27 cells to tcdB toxins. The C. difficile toxin caused cytotoxic effects on the cells, which resulted in a dose-dependent and time-dependent decrease in cell impedance. The RTCA assay possessed an analytical sensitivity of 0.2 ng/ml for C. difficile toxin B with no cross-reactions with other enterotoxins, nontoxigenic C. difficile, or other Clostridum species. Clinical validation was performed on 300 consecutively collected stool specimens from patients with suspected C. difficile infection (CDI). Each stool specimen was tested in parallel by a real-time PCR assay (PCR), a dual glutamate dehydrogenase and toxin A/B enzyme immunoassay (EIA), and the RTCA assay. In comparison to a reference standard in a combination of the three assays, the RTCA had a specificity of 99.6% and a sensitivity of 87.5% (28 of 32), which was higher than the EIA result (P = 0.005) but lower than the PCR result (P = 0.057). In addition, the RTCA assay allowed for quantification of toxin protein concentration in a given specimen. Among RTCA-positive specimens collected prior to treatment with metronidazole and/or vancomycin, a significant correlation between toxin protein concentrations and clinical CDI severities was observed (R-2 = 0.732, P = 0.0004). Toxin concentrations after treatment (0.89 ng/ml) were significantly lower than those prior to the treatment (15.68 ng/ml, Wilcoxon P = 0.01). The study demonstrates that the RTCA assay provides a functional tool for the potential assessment of C. difficile infections.
Impact of the Reverse Two-Step Algorithm for Clostridioides difficile Testing in the Microbiology Laboratory on Hospitalized Patients

Evann E Hilt,Byron P Vaughn,Alison L Galdys,Michael D Evans,Patricia Ferrieri

DOI: https://doi.org/10.1093/ofid/ofae244

2024-04-27

Open Forum Infectious Diseases

Abstract:Abstract Introduction Multistep laboratory testing is recommended for the diagnosis of Clostridioides difficile infection (CDI). The aim of this study was to present the impact of multistep CDI diagnostic testing in an academic hospital system and evaluate the toxin B gene PCR cycle threshold (Ct) values of PCR positive tests. Methods In October of 2022 our system began reflex testing all PCR positive stool samples with the C. DIFF QUIK CHEK COMPLETE® (Techlab; Blacksburg, VA), an EIA based test resulting the glutamate dehydrogenase antigen (GDH) and C difficile toxin A/B. Hospital-onset (HO) CDI and CDI antibiotics use before and after testing were tracked. Ct values were obtained from the Infectious Diseases Diagnostic Laboratory. Receiver operating curve analysis was used to examine the sensitivity and specificity for identifying GDH+/toxin + and GDH-/toxin- at various Ct thresholds. Results The HO-CDI rate decreased from 0.352 cases per 1000/pt-days to 0.115 cases per 1000/pt-days post reflex testing (p < 0.005). Anti-CDI antibiotics use decreased, but the decrease was not commensurate with CDI rates following reflex testing. PCR+/GDH+/toxin + samples had a lower mean Ct value than PCR+/GDH-/toxin- samples (23.3 versus 33.5, p < 0.0001). A Ct value of 28.65 could distinguish between those two groups. Fifty-four percent of PCR+/GDH+/toxin- samples had a Ct value below that cut-off, suggesting the possibility of CDI with a negative toxin test. Conclusions Reflex testing for a laboratory diagnosis of CDI results in rapid, system-wide decreases in the rate of HO-CDI. Additional research is needed to distinguish CDI from C. difficile colonization in patients with discordant testing.

immunology,infectious diseases,microbiology
Laboratory diagnosis of Clostridioides dif f icile infection: guidelines and status of practice in Korea

Hae-Sun Chung

DOI: https://doi.org/10.5145/acm.2024.27.1.2

2024-03-20

Annals of Clinical Microbiology

Abstract:Clostridioides difficile infection (CDI) is a common healthcare-associated infection that is expected to increase with the increases in the elderly population, immunocompromised patients treated with chemotherapy and immunosuppressive drugs, antimicrobial-resistant bacteria, and invasive medical technologies. Accurate diagnosis is critical for proper treatment and management of CDI. Clinical laboratories typically use four methods to diagnose CDI: C. difficile culture, toxin detection using immunoassays, detection of glutamate dehydrogenase using immunoassays, and detection of toxin A/B gene. Each CDI diagnostic test has strengths and limitations, and varies in performance. Guidelines for CDI diagnosis have been developed by organizations that include the European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America/Society for Healthcare Epidemiology of America, and American College of Gastroenterology. Certain other countries have guidelines. In Korea, surveys on CDI diagnosis performed in 2015 and 2018 revealed a shift in CDI testing in clinical laboratories in Korea. It is necessary to develop standardized diagnostic guidelines for CDI appropriate for the Korean context.
Genomic surveillance of Clostridioides difficile transmission and virulence in a healthcare setting

Erin P. Newcomer,Skye R. S. Fishbein,Kailun Zhang,Tiffany Hink,Kimberly A. Reske,Candice Cass,Zainab H. Iqbal,Emily L. Struttmann,Carey-Ann D. Burnham,Erik R. Dubberke,Gautam Dantas

DOI: https://doi.org/10.1128/mbio.03300-23

IF: 6.4

2024-02-09

mBio

Abstract:Clostridioides difficile infection remains a leading cause of hospital-associated diarrhea, despite increased antibiotic stewardship and transmission prevention strategies. This suggests a changing genomic landscape of C. difficile . Our study provides insight into the nature of prevalent C. difficile strains in a hospital setting and transmission patterns among carriers. Longitudinal sampling of surfaces and patient stool revealed that both toxigenic and nontoxigenic strains of C. difficile clade 1 dominate these two wards. Moreover, quantification of transmission in carriers of these clade 1 isolates underscores the need to revisit infection prevention measures in this patient group. We identified unique genetic signatures associated with virulence in this clade. Our data highlight the complexities of preventing transmission of this pathogen in a hospital setting and the need to investigate the mechanisms of in vivo persistence and virulence of prevalent lineages in the host gut microbiome.

microbiology
Molecular Characterization and Antibiotic Resistance of Clostridioides Difficile in Patients with Inflammatory Bowel Disease from Two Hospitals in China

Tao Lv,Lisi Zheng,Tao Wu,Ping Shen,Yunbo Chen

DOI: https://doi.org/10.1016/j.jgar.2022.06.017

IF: 4.349

2022-01-01

Journal of Global Antimicrobial Resistance

Abstract:Objectives: Patients with inflammatory bowel disease (IBD) are susceptible to Clostridioides difficile in-fection (CDI), resulting in poor outcomes and recurrence; therefore, the molecular characterization of C. difficile in IBD patients in China needs further investigation. Methods: C. difficile strains were isolated and identified from faecal samples of adult and paediatric IBD patients. Toxigenic strains were typed using multilocus sequence typing and whole genomic sequencing (WGS) to construct the phylogenetic tree. Susceptibility to 10 antimicrobials was evaluated using the Etest. Results: Among the 838 IBD patients, 82 toxigenic C. difficile were identified, which comprised 46 from adults and 36 children. A total of 90.2% (74/82) of the isolates were positive for both toxin A and toxin B genes (A + B + ), whereas the remaining 9.8% were negative for toxin A gene but positive for toxin B gene (A-B + ). These toxigenic strains were susceptible to metronidazole and vancomycin, but highly resistant to clindamycin, erythromycin, and fluoroquinolones. All moxifloxacin-resistant isolates had mutations re-sulting in an amino acid substitution in gryA (T82I). The dominant types were ST-35 (20.7%), ST-2 (17.1%), ST-54 (13.4%), and ST-3 (13.4%) in all patients. Conclusion: The incidence and molecular epidemiology of C. difficile infection in adult IBD patients re-sembled CDI in the general inpatient population. A higher antibiotic resistance rate was identified among the C. difficile isolates obtained from paediatric IBD patients than from adult patients, and a few STs ac-counted for most multidrug-resistant strains. However, the molecular genetic features of the same ST type between these two groups remains highly correlated. (c) 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
Molecular Epidemiology and Antimicrobial Susceptibility of Clostridium Difficile Isolated from Hospitals During a 4-Year Period in China.

Yun-Bo Chen,Si-Lan Gu,Ping Shen,Tao Lv,Yun-Hui Fang,Ling-Ling Tang,Lan-Juan Li

DOI: https://doi.org/10.1099/jmm.0.000646

2018-01-01

Abstract:Objective. The aim of this study was to perform molecular characterization for and determine the antimicrobial susceptibility profiles of Clostridium difficile collected from hospitals during a 4-year period (2009-2013) in China. Methods. Strains of toxigenic C. difficile were isolated from patients with diarrhoea, and this was followed by typing using multilocus sequence typing (MLST) and testing for susceptibility to 10 antimicrobials by using the E-test. The mechanisms of resistance to moxifloxacin, erythromycin, clindamycin and tetracycline were investigated by PCR. Results. A total of 405 non-duplicate toxigenic C. difficile isolates were identified, while 31 sequence types (STs) were identified. A predominant type, ST-54, accounted for 20.2% of the STs, followed by ST-35 (16.3 %) and ST-37 (13.6 %). We found that 6.2% of the isolates were binary toxin genes-positive, and 83.7% of these belonged to ST-5. All of the isolates demonstrated 100% susceptibility to first-line Clostridium difficile infection (CDI) therapies (i.e. metronidazole and vancomycin), while the resistance rates varied for the other antibiotics tested. Two hundred and ninety three (72.3 %) isolates were susceptible to moxifloxacin. All 112 moxifloxacin-resistant isolates had mutations resulting in an amino acid substitution in gryA and/or gyrB. The ermB gene was detected in 86.7% (241/278) of the erythromycin-and clindamycin-resistant isolates, while the tet M gene was present in 97.1% (85/87) of the tetracycline-resistant isolates. Conclusion. MLST typing revealed a wide variety of STs causing CDI, while ST-54 was the most common ST. All of the isolates were susceptible to metronidazole and vancomycin, while the resistance rates varied for the other antibiotics tested. There were no changes in the trends for the STs and antibiotic susceptibility profiles over 4 years.
Clostridioides difficile Infections in Children: What Is the Optimal Laboratory Diagnostic Method?

Mohammed Suleiman,Patrick Tang,Omar Imam,Princess Morales,Diyna Altrmanini,Jill C Roberts,Andrés Pérez-López

DOI: https://doi.org/10.3390/microorganisms12091785

IF: 4.5

2024-08-28

Microorganisms

Abstract:The diagnosis of Clostridioides difficile infection (CDI) in the pediatric population is complicated by the high prevalence of asymptomatic colonization, particularly in infants. Many laboratory diagnostic methods are available, but there continues to be controversy over the optimal laboratory testing approach to diagnose CDI in children. We evaluated commonly used C. difficile diagnostic commercial tests in our pediatric hospital population at Sidra Medicine in Doha, Qatar. Between June and December 2023, 374 consecutive stool samples from pediatric patients aged 0-18 years old were tested using: Techlab C. diff Quik Chek Complete, Cepheid GeneXpert C. difficile, QIAstat-Dx Gastrointestinal Panel, and culture using CHROMagar C. difficile. The results of these tests as standalone methods or in four different testing algorithms were compared to a composite reference method on the basis of turnaround time, ease of use, cost, and performance characteristics including specificity, sensitivity, negative predictive value, and positive predictive value. Our study showed variability in test performance of the different available assays in diagnosing CDI. In our population, a testing algorithm starting with Cepheid GeneXpert C. difficile PCR assay or QIAstat-Dx Gastrointestinal panel as a screening test followed by toxin immunoassay for positive samples using the Techlab C. diff Quik Chek Complete kit showed the best performance (100% specificity and 100% positive predictive value) when combined with clinical review of the patient to assess risk factors for CDI, clinical presentation, and alternative causes of diarrhea.
Hypothyroidism presenting as destructive arthropathy of the fingers.

J. Gerster,P. Quadri,Y. Saudan

DOI: https://doi.org/10.1136/pgmj.61.712.157

1985-02-01

Postgraduate Medical Journal

Abstract:A patient presenting with destructive arthropathy of the proximal interphalangeal (PIP) joints of the hands is described. She was initially believed to have rheumatoid arthritis but non-steroidal anti-inflammatory drugs were of no help. The patient was subsequently found to have hypothyroidism and erosive osteoarthritis of the fingers. Joint swelling, pain and stiffness responded dramatically to thyroid hormone substitution. The PIP joint spaces reappeared on the radiographs within 9 months. This case suggest that hypothyroidism may induce destructive arthropathy of the finger joints. As thyroxine replacement may reverse the rheumatic complaints, hypothyroidism should be considered in the differential diagnosis of a destructive arthropathy of unclear aetiology.
S256 Impact of Patient and Provider Variability on Compliance With C. difficile Testing for IBD Flares

Danielle Garfunkel,Daniel Alvarez,George G. Papadopoulos,Hamza Sadhra,Melissa Fazzari,Ruby Greywoode,Thomas Ullman

DOI: https://doi.org/10.14309/01.ajg.0001030392.40068.cb

2024-10-26

The American Journal of Gastroenterology

Abstract:Over 3 decades, the incidence of Clostridioides difficile ( C. diff ) in inflammatory bowel disease (IBD) patients has risen dramatically. Though guidelines advise testing all patients with IBD flares for C. diff , there is little data on compliance with this recommendation. This study investigates C. diff testing compliance rates, factors affecting testing and impact of testing in IBD flares on length of stay (LOS) and readmissions.

gastroenterology & hepatology
Diagnostic yield of repeat sampling with immunoassay, real-time PCR, and toxigenic culture for the detection of toxigenic Clostridium difficile in an epidemic and a non-epidemic setting

J. van Prehn,C. M. J. E. Vandenbroucke-Grauls,Y. H. van Beurden,R. van Houdt,S. Vainio,C. W. Ang

DOI: https://doi.org/10.1007/s10096-015-2484-9

2015-09-16

Abstract:Current international guidelines lack definite conclusions regarding repeat stool sampling for the detection of toxigenic Clostridium difficile. We assessed the value of repeat sampling and compared the diagnostic yield in an epidemic to a non-epidemic setting. Consecutive fecal samples obtained during two time frames were analyzed using direct stool immunoassay toxin testing (enzyme immunoassay [EIA]), direct stool real-time PCR toxin gene testing, and toxigenic culture. Samples collected within 7 days of the initial sample were considered repeat tests. In the epidemic setting 989 patients were analyzed, and in the non-epidemic setting 1,015. In the epidemic setting 204 patients had two or more specimens included for analysis and in the non-epidemic setting 287 patients. In the epidemic setting 136 samples yielded a positive results, either by EIA or toxigenic culture; of these, 108 were positive according to EIA and 123 according to toxigenic culture. In the first test round 98 (90.7 %, 95 % CI 85.3 to 96.2), 114 (92.7 %, 88.1 to 97.3), and 126 (92.6 %, 88.3 to 97.0) positives were detected. Subsequent test rounds yielded 10 (9.3 %, 3.8 to 14.7), 9 (7.3 %, 2.7 to 11.9), and 10 (7.4 %, 3.0 to 11.7) extra positives. In the non-epidemic setting EIA, toxigenic culture and PCR detected 33, 66, and 83 positives. The three tests combined 93 detected positives. In the first test round 30 (90.9 %, 81.1 to 100.7), 63 (95.5 %, 90.4 to 110.5), 76 (91.6 %, 85.6 to 97.5), and 87 (93.5 %, 88.6 to 98.5) positives were detected. Subsequent test rounds yielded 3 (9.1 %, −0.7 to 18.9), 3 (4.5 %, −0.5 to 9.6), 7 (8.4 %, 2.5 to 14.4), and 6 (6.5 %, 1.5 to 11.4) extra positives. In conclusion, repeat testing resulted in 4.5 % to 9.3 % extra positives. No significant difference between the settings studied could be demonstrated. Repeat sampling and multimodality testing may be chosen in an outbreak situation to detect all cases, effectively controlling nosocomial spread.

infectious diseases,microbiology
Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile

Mariachiara Mengoli,Monica Barone,Marco Fabbrini,Federica D'Amico,Patrizia Brigidi,Silvia Turroni

DOI: https://doi.org/10.3390/genes13122200

2022-11-24

Abstract:Clostridioides difficile is an obligate anaerobic pathogen among the most common causes of healthcare-associated infections. It poses a global threat due to the clinical outcomes of infection and resistance to antibiotics recommended by international guidelines for its eradication. In particular, C. difficile infection can lead to fulminant colitis associated with shock, hypotension, megacolon, and, in severe cases, death. It is therefore of the utmost urgency to fully characterize this pathogen and better understand its spread, in order to reduce infection rates and improve therapy success. This review aims to provide a state-of-the-art overview of the genetic variation of C. difficile, with particular regard to pathogenic genes and the correlation with clinical issues of its infection. We also summarize the current typing techniques and, based on them, the global distribution of the most common ribotypes. Finally, we discuss genomic surveillance actions and new genetic engineering strategies as future perspectives to make it less difficile.
Prevalence and Strain Characterization of Clostridioides (Clostridium) difficile in Representative Regions of Germany, Ghana, Tanzania and Indonesia – A Comparative Multi-Center Cross-Sectional Study

Mwanaisha Seugendo,Iryna Janssen,Vanessa Lang,Irene Hasibuan,Wolfgang Bohne,Paul Cooper,Rolf Daniel,Katrin Gunka,R. L. Kusumawati,Stephen E. Mshana,Lutz von Müller,Benard Okamo,Jan R. Ortlepp,Jörg Overmann,Thomas Riedel,Maja Rupnik,Ortrud Zimmermann,Uwe Groß

DOI: https://doi.org/10.3389/fmicb.2018.01843

IF: 5.2

2018-08-07

Frontiers in Microbiology

Abstract:Clostridioides (Clostridium) difficile infections (CDI) are considered worldwide as emerging health threat. Uptake of C. difficile spores may result in asymptomatic carrier status or lead to CDI that could range from mild diarrhea, eventually developing into pseudomembranous colitis up to a toxic megacolon that often results in high mortality. Most epidemiological studies to date have been performed in middle- and high income countries. Beside others, the use of antibiotics and the composition of the microbiome have been identified as major risk factors for the development of CDI. We therefore postulate that prevalence rates of CDI and the distribution of C. difficile strains differ between geographical regions depending on the regional use of antibiotics and food habits. A total of 593 healthy control individuals and 608 patients suffering from diarrhea in communities in Germany, Ghana, Tanzania and Indonesia were selected for a comparative multi-center cross-sectional study. The study populations were screened for the presence of C. difficile in stool samples. Cultured C. difficile strains (n = 84) were further subtyped and characterized using PCR-ribotyping, determination of toxin production, and antibiotic susceptibility testing. Prevalence rates of C. difficile varied widely between the countries. Whereas high prevalence rates were observed in symptomatic patients living in Germany and Indonesia (24.0 and 14.7%), patients from Ghana and Tanzania showed low detection rates (4.5 and 6.4%). Differences were also obvious for ribotype distribution and toxin repertoires. Toxin A+/B+ ribotypes 001/072 and 078 predominated in Germany, whereas most strains isolated from Indonesian patients belonged to toxin A+/B+ ribotype SLO160 and toxin A-/B+ ribotype 017. With 42.9-73.3%, non-toxigenic strains were most abundant in Africa, but were also found in Indonesia at a rate of 18.2%. All isolates were susceptible to vancomycin and metronidazole. Mirroring the antibiotic use, however, moxifloxacin resistance was absent in African C. difficile isolates but present in Indonesian (24.2%) and German ones (65.5%). This study showed that CDI is a global health threat with geographically different prevalence rates which might reflect distinct use of antibiotics. Significant differences for distributions of ribotypes, toxin production, and antibiotic susceptibilities were observed.

microbiology

Diagnostic testing for Clostridium difficile: a comprehensive survey of laboratories in England.

Diagnosis of Clostridioides difficile infection and impact of testing

Diagnostic Guidance for C. difficile Infections

Epidemiological and clinical characteristics of Clostridium difficile infection in patients with refractory inflammatory bowel disease

High Prevalence of Multistep Algorithms in Diagnostic Clostridioides difficile Laboratory Testing

Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018

Clostridium difficile Diagnostics in Long-Term Care Facilities

Nationwide Survey for Current Status of Laboratory Diagnosis of Clostridioides difficile Infection in Korea

Assessment Of Clostridium Difficile Infections By Quantitative Detection Of Tcdb Toxin By Use Of A Real-Time Cell Analysis System

Impact of the Reverse Two-Step Algorithm for Clostridioides difficile Testing in the Microbiology Laboratory on Hospitalized Patients

Laboratory diagnosis of Clostridioides dif f icile infection: guidelines and status of practice in Korea

Genomic surveillance of Clostridioides difficile transmission and virulence in a healthcare setting

Molecular Characterization and Antibiotic Resistance of Clostridioides Difficile in Patients with Inflammatory Bowel Disease from Two Hospitals in China

Molecular Epidemiology and Antimicrobial Susceptibility of Clostridium Difficile Isolated from Hospitals During a 4-Year Period in China.

Clostridioides difficile Infections in Children: What Is the Optimal Laboratory Diagnostic Method?

Hypothyroidism presenting as destructive arthropathy of the fingers.

S256 Impact of Patient and Provider Variability on Compliance With C. difficile Testing for IBD Flares

Diagnostic yield of repeat sampling with immunoassay, real-time PCR, and toxigenic culture for the detection of toxigenic Clostridium difficile in an epidemic and a non-epidemic setting

Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile

Prevalence and Strain Characterization of Clostridioides (Clostridium) difficile in Representative Regions of Germany, Ghana, Tanzania and Indonesia – A Comparative Multi-Center Cross-Sectional Study